Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted

被引:69
|
作者
Yamanaka, H [1 ]
Nakajima, M [1 ]
Nishimura, K [1 ]
Yoshida, R [1 ]
Fukami, T [1 ]
Katoh, M [1 ]
Yokoi, T [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan
关键词
nicotine; LC-MS/MS; CYP2A6; poor metabolizer;
D O I
10.1016/j.ejps.2004.04.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Generally, 70-80% of absorbed nicotine is mainly metabolized to cotinine by cytochrome P450 (CYP) 2A6. There is genetic polymorphism in the human CYP2A6 gene. Among several mutated alleles, CYP2A6*4 allele is a whole deleted type. The purpose of the present study was to clarify the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for nicotine and its nine metabolites. Excretion levels of nicotine and its metabolites in 24 h accumulated urine after the chewing of one piece of nicotine gum were evaluated in five Japanese subjects whose CYP2A6 genotype was determined. In three subjects with CYP2A6*1A/CYP2A6*1A, CYP2A6*1A/CYP2A6*1B, and CYP2A6*1A/CYP2A6*4 (group I), nicotine was mainly excreted as cotinine, trans-3'-hydroxycotinine, and their glucuronide (approximately 60%). In contrast, in two subjects with CYP2A6*4/CYP2A6*4 (group II), trace levels of cotinine, cotinine N-glucuronide, and cotinine 1'-N-oxide were detected. Trans-3'-hydroxycotinine and its O-glucuronide were not detected. The excretion levels of nicotine itself, nicotine N-glucuronide, and nicotine 1'-N-oxide were higher than those in the other three subjects. The total excretion levels of these three compounds were approximately 95% in group II versus 35% in group I. However, the sum of the excretion levels of nicotine and all metabolites was similar among these five subjects. This is the first report of the metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 50 条
  • [1] CYP2A6 gene polymorphisms impact to nicotine metabolism
    Muliaty, Dewi
    Yusuf, Irawan
    Setiabudy, Rianto
    Wanandi, Septelia I.
    MEDICAL JOURNAL OF INDONESIA, 2010, 19 (01) : 46 - 51
  • [2] Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism
    Ring, Huijun Z.
    Valdes, Ana M.
    Nishita, Denise M.
    Prasad, Suman
    Jacob, Peyton, III
    Tyndale, Rachel F.
    Swan, Gary E.
    Benowitz, Neal L.
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (12): : 1007 - 1015
  • [3] The role of CYP2A6*2 in nicotine metabolism
    Riexinger, A
    Collins, S
    Gaertner, I
    Farger, G
    Batra, A
    NICOTINE & TOBACCO RESEARCH, 2005, 7 (04) : 653 - 653
  • [4] Genetic variability in CYP2A6 and the pharmacokinetics of nicotine
    Mwenifiumbo, Jill C.
    Tyndale, Rachel F.
    PHARMACOGENOMICS, 2007, 8 (10) : 1385 - 1402
  • [5] CYP2A6 polymorphism and nicotine metabolism.
    Benowitz, NL
    Tyndale, R
    Jacob, P
    Swan, GE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P41 - P41
  • [6] CYP2A6 polymorphism, nicotine, and environmental nitrosamines
    Idle, JR
    LANCET, 1999, 353 (9169): : 2073 - 2073
  • [7] Association Between Nicotine Metabolism and CYP2A6*1 and CYP2A6*4 Genotypes in an Iranian Population
    Heravi, Reza Entezari
    Ramezani, Mohammad
    Behravan, Javad
    DNA AND CELL BIOLOGY, 2010, 29 (07) : 369 - 373
  • [8] Genetic polymorphisms in human Cyp2a6 gene and interindividual differences in nicotine metabolism
    Nakajima, M
    Yoshida, R
    Nishimura, K
    Kwon, JT
    Yokoi, T
    CYTOCHROMES P450, BIOCHEMISTRY, BIOPHYSICS AND DRUG METABOLISM, 2003, : 257 - 260
  • [9] Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6)
    Chen, Li-Shiun
    Bloom, A. Joseph
    Baker, Timothy B.
    Smith, Stevens S.
    Piper, Megan E.
    Martinez, Maribel
    Saccone, Nancy
    Hatsukami, Dorothy
    Goate, Alison
    Bierut, Laura
    ADDICTION, 2014, 109 (01) : 128 - 137
  • [10] Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism
    Yoshida, R
    Nakajima, M
    Watanabe, Y
    Kwon, JT
    Yokoi, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) : 511 - 517